Wooseong Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4596651/publications.pdf

Version: 2024-02-01

		236925	233421
80	2,382	25	45
papers	citations	h-index	g-index
80	80	80	3330
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Generation of Recombinant Antibodies in HEK293F Cells for the Detection of <i>Staphylococcus aureus</i> . ACS Omega, 2022, 7, 9690-9700.	3.5	3
2	Finding of novel polyhydroxybutyrate producer Loktanella sp. SM43 capable of balanced utilization of glucose and xylose from lignocellulosic biomass. International Journal of Biological Macromolecules, 2022, 208, 809-818.	7.5	21
3	Antimicrobial activity of the membrane-active compound nTZDpa is enhanced at low pH. Biomedicine and Pharmacotherapy, 2022, 150, 112977.	5.6	6
4	Topical niclosamide (ATx201) reduces <i>Staphylococcus aureus</i> colonization and increases Shannon diversity of the skin microbiome in atopic dermatitis patients in a randomized, doubleâ€blind, placeboâ€controlled Phase 2 trial. Clinical and Translational Medicine, 2022, 12, e790.	4.0	15
5	4-Chloro-2-Isopropyl-5-Methylphenol Exhibits Antimicrobial and Adjuvant Activity against Methicillin-Resistant <i>Staphylococcus aureus</i> Journal of Microbiology and Biotechnology, 2022, 32, 730-739.	2.1	2
6	Leucyl-tRNA Synthetase Inhibitor, D-Norvaline, in Combination with Oxacillin, Is Effective against Methicillin-Resistant Staphylococcus aureus. Antibiotics, 2022, 11, 683.	3.7	2
7	Wastewater based microalgal biorefinery for bioenergy production: Progress and challenges. Science of the Total Environment, 2021, 751, 141599.	8.0	177
8	Increased Antibiotic Resistance of Methicillin-Resistant <i>Staphylococcus aureus</i> USA300 \hat{l} " <i>psm</i> Mutants and a Complementation Study of \hat{l} " <i>psm</i> Mutants Using Synthetic Phenol-Soluble Modulins. Journal of Microbiology and Biotechnology, 2021, 31, 115-122.	2.1	10
9	Repurposing Kinase Inhibitor Bay 11-7085 to Combat Staphylococcus aureus and Candida albicans Biofilms. Frontiers in Pharmacology, 2021, 12, 675300.	3.5	11
10	Comparative Study of the Difference in Behavior of the Accessory Gene Regulator (Agr) in USA300 and USA400 Community-Associated Methicillin-Resistant <i>Staphylococcus aureus</i> (CA-MRSA). Journal of Microbiology and Biotechnology, 2021, 31, 1060-1068.	2.1	9
11	Structure–Activity Relationship and Anticancer Profile of Second-Generation Anti-MRSA Synthetic Retinoids. ACS Medicinal Chemistry Letters, 2020, 11, 393-397.	2.8	12
12	5-Aminosalicylic Acid Azo-Coupled with a GPR109A Agonist Is a Colon-Targeted Anticolitic Codrug with a Reduced Risk of Skin Toxicity. Molecular Pharmaceutics, 2020, 17, 167-179.	4.6	14
13	New Antimicrobial Bioactivity against Multidrug-Resistant Gram-Positive Bacteria of Kinase Inhibitor IMD0354. Antibiotics, 2020, 9, 665.	3.7	10
14	Multi-omics based characterization of antibiotic response in clinical isogenic isolates of methicillin-susceptible/resistant <i>Staphylococcus aureus</i> . RSC Advances, 2020, 10, 27864-27873.	3.6	7
15	Preparation and Evaluation of Amino Acid Conjugates of Celecoxib as Prodrugs to Improve the Pharmacokinetic and Therapeutic Properties of Celecoxib. Pharmaceutics, 2020, 12, 1043.	4.5	1
16	Combination Therapy Using Low-Concentration Oxacillin with Palmitic Acid and Span85 to Control Clinical Methicillin-Resistant Staphylococcus aureus. Antibiotics, 2020, 9, 682.	3.7	12
17	In the Model Host Caenorhabditis elegans, Sphingosine-1-Phosphate-Mediated Signaling Increases Immunity toward Human Opportunistic Bacteria. International Journal of Molecular Sciences, 2020, 21, 7813.	4.1	8
18	Anti-MRSA agent discovery using Caenorhabditis elegans-based high-throughput screening. Journal of Microbiology, 2020, 58, 431-444.	2.8	10

#	Article	IF	CITATIONS
19	<scp><i>Caenorhabditis elegans</i></scp> mounts a p38 <scp>MAPK</scp> pathwayâ€mediated defence to <i>Cutibacterium acnes</i> i>infection. Cellular Microbiology, 2020, 22, e13234.	2.1	13
20	Simultaneous monitoring of the bioconversion from lysine to glutaric acid by ethyl chloroformate derivatization and gas chromatography-mass spectrometry. Analytical Biochemistry, 2020, 597, 113688.	2.4	4
21	Phenol-Soluble Modulin-Mediated Aggregation of Community-Associated Methicillin-Resistant Staphylococcus Aureus in Human Cerebrospinal Fluid. Cells, 2020, 9, 788.	4.1	9
22	The Neutrally Charged Diarylurea Compound PQ401 Kills Antibiotic-Resistant and Antibiotic-Tolerant Staphylococcus aureus. MBio, 2020, 11 , .	4.1	23
23	Production of L-Theanine Using <i>Escherichia coli</i> Whole-Cell Overexpressing γ-Glutamylmethylamide Synthetase with Baker's Yeast. Journal of Microbiology and Biotechnology, 2020, 30, 785-792.	2.1	16
24	A colon-specific prodrug of metoclopramide ameliorates colitis in an experimental rat model. Drug Design, Development and Therapy, 2019, Volume 13, 231-242.	4.3	7
25	Colon-Targeted Delivery Facilitates the Therapeutic Switching of Sofalcone, a Gastroprotective Agent, to an Anticolitic Drug via Nrf2 Activation. Molecular Pharmaceutics, 2019, 16, 4007-4016.	4.6	10
26	A selective membrane-targeting repurposed antibiotic with activity against persistent methicillin-resistant <i>Staphylococcus aureus</i> . Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 16529-16534.	7.1	117
27	Auranofin is an effective agent against clinical isolates of <i>Staphylococcus aureus</i> Medicinal Chemistry, 2019, 11, 1417-1425.	2.3	18
28	Sofalcone, a gastroprotective drug, covalently binds to KEAP1 to activate Nrf2 resulting in anti-colitic activity. European Journal of Pharmacology, 2019, 865, 172722.	3.5	17
29	Conjugation of Amisulpride, an Anti-Psychotic Agent, with 5-Aminosalicylic Acid via an Azo Bond Yields an Orally Active Mutual Prodrug against Rat Colitis. Pharmaceutics, 2019, 11, 585.	4.5	7
30	Therapeutic switching of sulpiride, an anti-psychotic and prokinetic drug, to an anti-colitic drug using colon-specific drug delivery. Drug Delivery and Translational Research, 2019, 9, 334-343.	5.8	11
31	Antimicrobial Drug Discovery Against Persisters. , 2019, , 273-295.		2
32	Mesalazine Activates Adenosine Monophosphate-activated Protein Kinase: Implication in the Anti-inflammatory Activity of this Anti-colitic Drug. Current Molecular Pharmacology, 2019, 12, 272-280.	1.5	16
33	Antibacterial Properties of Four Novel Hit Compounds from a Methicillin-Resistant <i>Staphylococcus aureus–Caenorhabditis elegans</i> High-Throughput Screen. Microbial Drug Resistance, 2018, 24, 666-674.	2.0	25
34	Enhanced isobutanol production from acetate by combinatorial overexpression of acetylâ€CoA synthetase and anaplerotic enzymes in engineered <i>Escherichia coli</i> Bioengineering, 2018, 115, 1971-1978.	3.3	58
35	A new class of synthetic retinoid antibiotics effective against bacterial persisters. Nature, 2018, 556, 103-107.	27.8	307
36	Antimicrobial activity of 1,3,4-oxadiazole derivatives against planktonic cells and biofilm of <i>Staphylococcus aureus</i> . Future Medicinal Chemistry, 2018, 10, 283-296.	2.3	46

#	Article	IF	CITATIONS
37	Strategies against methicillin-resistant <i>Staphylococcus aureus (i) persisters. Future Medicinal Chemistry, 2018, 10, 779-794.</i>	2.3	31
38	Novel \hat{l}^2 -phenylacrylic acid derivatives exert anti-cancer activity by inducing Src-mediated apoptosis in wild-type KRAS colon cancer. Cell Death and Disease, 2018, 9, 877.	6.3	0
39	Colon-targeted dexamethasone microcrystals with pH-sensitive chitosan/alginate/Eudragit S multilayers for the treatment of inflammatory bowel disease. Carbohydrate Polymers, 2018, 198, 434-442.	10.2	62
40	Minoxidil Induction of VEGF Is Mediated by Inhibition of HIF-Prolyl Hydroxylase. International Journal of Molecular Sciences, 2018, 19, 53.	4.1	34
41	Butyrate-based n-butanol production from an engineered Shewanella oneidensis MR-1. Bioprocess and Biosystems Engineering, 2018, 41, 1195-1204.	3.4	20
42	Discovery and Optimization of nTZDpa as an Antibiotic Effective Against Bacterial Persisters. ACS Infectious Diseases, 2018, 4, 1540-1545.	3.8	33
43	Influence of subinhibitory concentrations of NH125 on biofilm formation & Dividence factors of <i>Staphylococcus aureus</i> . Future Medicinal Chemistry, 2018, 10, 1319-1331.	2.3	13
44	Is it worth expending energy to convert biliverdin into bilirubin?. Free Radical Biology and Medicine, 2018, 124, 232-240.	2.9	22
45	Enhanced isobutanol production from acetate by combinatorial overexpression of acetyl-CoA synthetase and anaplerotic enzymes in engineered <i>Escherichia coli</i> . Biotechnology and Bioengineering, 2018, 115, 1971.	3.3	34
46	An update on the use of i>C. elegans ip for preclinical drug discovery: screening and identifying anti-infective drugs. Expert Opinion on Drug Discovery, 2017, 12, 625-633.	5.0	34
47	Synergistic Efficacy of Aedes aegypti Antimicrobial Peptide Cecropin A2 and Tetracycline against Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	56
48	Oxidized 5-aminosalicylic acid activates Nrf2-HO-1 pathway by covalently binding to Keap1: Implication in anti-inflammatory actions of 5-aminosalicylic acid. Free Radical Biology and Medicine, 2017, 108, 715-724.	2.9	24
49	Increase in furfural tolerance by combinatorial overexpression of NAD salvage pathway enzymes in engineered isobutanol-producing E. coli. Bioresource Technology, 2017, 245, 1430-1435.	9.6	40
50	Rebamipide induces the gastric mucosal protective factor, cyclooxygenase-2, via activation of $5a \in ^2$ -AMP-activated protein kinase. Biochemical and Biophysical Research Communications, 2017, 483, 449-455.	2.1	4
51	Production of itaconate by whole-cell bioconversion of citrate mediated by expression of multiple cis-aconitate decarboxylase (cadA) genes in Escherichia coli. Scientific Reports, 2017, 7, 39768.	3.3	30
52	The role of NdgR in glycerol metabolism in Streptomyces coelicolor. Bioprocess and Biosystems Engineering, 2017, 40, 1573-1580.	3.4	6
53	Characterization of a Francisella tularensis-Caenorhabditis elegans Pathosystem for the Evaluation of Therapeutic Compounds. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	21
54	Conjugation of metronidazole with dextran: a potential pharmaceutical strategy to control colonic distribution of the anti-amebic drug susceptible to metabolism by colonic microbes. Drug Design, Development and Therapy, 2017, Volume11, 419-429.	4.3	12

#	Article	IF	CITATIONS
55	L-Glycine Alleviates Furfural-Induced Growth Inhibition during Isobutanol Production in Escherichia coli. Journal of Microbiology and Biotechnology, 2017, 27, 2165-2172.	2.1	5
56	5-Aminosalicylic Acid Azo-Linked to Procainamide Acts as an Anticolitic Mutual Prodrug via Additive Inhibition of Nuclear Factor kappaB. Molecular Pharmaceutics, 2016, 13, 2126-2135.	4.6	15
57	Raf-kinase inhibitor GW5074 shows antibacterial activity against methicillin-resistant <i>Staphylococcus aureus</i> and potentiates the activity of gentamicin. Future Medicinal Chemistry, 2016, 8, 1941-1952.	2.3	9
58	NH125 kills methicillin-resistant <i>Staphylococcus aureus</i> persisters by lipid bilayer disruption. Future Medicinal Chemistry, 2016, 8, 257-269.	2.3	36
59	Dextran-5-(4-ethoxycarbonylphenylazo)salicylic acid ester, a polymeric colon-specific prodrug releasing 5-aminosalicylic acid and benzocaine, ameliorates TNBS-induced rat colitis. Journal of Drug Targeting, 2016, 24, 468-474.	4.4	8
60	Evaluation of glycine-bearing celecoxib derivatives as a colon-specific mutual prodrug acting on nuclear factor-κB, an anti-inflammatory target. Drug Design, Development and Therapy, 2015, 9, 4227.	4.3	3
61	Colon-targeted delivery of piceatannol enhances anti-colitic effects of the natural product: potential molecular mechanisms for therapeutic enhancement. Drug Design, Development and Therapy, 2015, 9, 4247.	4.3	7
62	Repurposing Salicylanilide Anthelmintic Drugs to Combat Drug Resistant Staphylococcus aureus. PLoS ONE, 2015, 10, e0124595.	2.5	123
63	Identification of an Antimicrobial Agent Effective against Methicillin-Resistant Staphylococcus aureus Persisters Using a Fluorescence-Based Screening Strategy. PLoS ONE, 2015, 10, e0127640.	2.5	57
64	Celecoxib coupled to dextran via a glutamic acid linker yields a polymeric prodrug suitable for colonic delivery. Drug Design, Development and Therapy, 2015, 9, 4105.	4.3	6
65	HIF-prolyl hydroxylase is a potential molecular target for esculetin-mediated anti-colitic effects. Fìtoterapìâ, 2015, 103, 55-62.	2.2	16
66	Colonic delivery of celecoxib is a potential pharmaceutical strategy for repositioning the selective COX-2 inhibitor as an anti-colitic agent. Archives of Pharmacal Research, 2015, 38, 1830-1838.	6.3	10
67	Antibacterial properties of 3-(phenylsulfonyl)-2-pyrazinecarbonitrile. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 5203-5207.	2.2	14
68	Lipophilic modification enhances anti-colitic properties of rosmarinic acid by potentiating its HIF-prolyl hydroxylases inhibitory activity. European Journal of Pharmacology, 2015, 747, 114-122.	3.5	14
69	A Defensin from the Model Beetle Tribolium castaneum Acts Synergistically with Telavancin and Daptomycin against Multidrug Resistant Staphylococcus aureus. PLoS ONE, 2015, 10, e0128576.	2.5	32
70	Phospholipase D activates HIF-1-VEGF pathway via phosphatidic acid. Experimental and Molecular Medicine, 2014, 46, e126-e126.	7.7	29
71	N-(2-mercaptopropionyl)-glycine, a diffusible antioxidant, activates HIF-1 by inhibiting HIF prolyl hydroxylase-2: Implication in amelioration of rat colitis by the antioxidant. Biochemical and Biophysical Research Communications, 2014, 443, 1008-1013.	2.1	4
72	Enzyme/pH dual sensitive polymeric nanoparticles for targeted drug delivery to the inflamed colon. Colloids and Surfaces B: Biointerfaces, 2014, 123, 271-278.	5.0	70

#	Article	IF	CITATION
73	Caffeic acid phenethyl ester activation of Nrf2 pathway is enhanced under oxidative state: Structural analysis and potential as a pathologically targeted therapeutic agent in treatment of colonic inflammation. Free Radical Biology and Medicine, 2013, 65, 552-562.	2.9	47
74	Effect of spaceflight on Pseudomonas aeruginosa final cell density is modulated by nutrient and oxygen availability. BMC Microbiology, 2013, 13, 241.	3.3	59
75	Spaceflight Promotes Biofilm Formation by Pseudomonas aeruginosa. PLoS ONE, 2013, 8, e62437.	2.5	153
76	Characterization of a new ScbR-like \hat{I}^3 -butyrolactone binding regulator (SlbR) in Streptomyces coelicolor. Applied Microbiology and Biotechnology, 2012, 96, 113-121.	3.6	19
77	A novel function of Streptomyces integration host factor (sIHF) in the control of antibiotic production and sporulation in Streptomyces coelicolor. Antonie Van Leeuwenhoek, 2012, 101, 479-492.	1.7	23
78	An integrative approach for high-throughput screening and characterization of transcriptional regulators in Streptomyces coelicolor. Pure and Applied Chemistry, 2010, 82, 57-67.	1.9	1
79	Mass spectrometric screening of transcriptional regulators involved in antibiotic biosynthesis in Streptomyces coelicolor A3(2). Journal of Industrial Microbiology and Biotechnology, 2009, 36, 1073-1083.	3.0	53
80	NdgR, an IclR-like regulator involved in amino-acid-dependent growth, quorum sensing, and antibiotic production in Streptomyces coelicolor. Applied Microbiology and Biotechnology, 2009, 82, 501-511.	3.6	57